Navigation Links
Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
Date:5/26/2009

ROCKVILLE, Md., May 26 /PRNewswire/ -- Theranostics Health, Inc. (TH) is pleased to announce its involvement in a five-year clinical research study funded by the Susan G. Komen Foundation. TH's collaborator, Duke University, was the recipient of a Promise Grant, part of over $25 million of investment by the foundation in 2009 to further the development of new prevention and treatment options for breast cancer.

The Susan G. Komen for the Cure(R) is a nonprofit organization dedicated to improving the lives of breast cancer patients through funding groundbreaking research. Since its inception nearly 30 years ago, the foundation has invested over $400 million. This year alone, grants will go to 54 universities and hospitals in 26 states and one foreign country, all for addressing the challenges associated with breast cancer.

Theranostics Health has been collaborating with researchers at Duke University as part of the collaboration agreement established in May 2008. Studies conducted by Theranostics Health with Dr. Victoria Seewaldt, MD, a Duke investigator, have provided the underlying rationale and preliminary data in support of the research proposed for the Promise Grant. Dr. Seewaldt is dedicated to discovering and developing new prevention and treatment strategies for each of her patients afflicted with breast cancer.

Theranostics Health will use its pathway mapping platform to measure signaling pathway activation in hundreds of key signaling proteins directly from randomly obtained periareolar breast fine-needle aspiration to assess individual response to chemoprevention in high-risk patients. This information can be used to develop a rapid test that matches the right prevention agent to each patient based on the biology of abnormal cells in each woman's body.

"The power of this new technology is that it gives us the possibility of tracking how a woman is or is not responding to a prevention drug," said Dr. Victoria Seewaldt. "If this project is successful, it will pave the way for quickly testing the effectiveness of prevention drugs as well as biological response to exercise."

"We are very pleased to have the opportunity of working with first-class research clinicians like Dr. Seewaldt. We share the same vision as Dr. Seewaldt in that each patient's tumor is different and an individualized assessment and approach is needed to effectively prevent and treat diseases," noted Dr. Danong Chen, President and CEO of Theranostics Health.

About Theranostics Health

Theranostics Health (TH) is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). TH's proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from many different types of cells usually present in a clinical biopsy. Therefore, information derived from subsequent molecular assays is specific to that cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. TH has an exclusive license from the National Institute of Health (NIH) to commercialize microdissection, including LCM, combined with protein analysis for cancer diagnostics and companion diagnostics. While providing research and development services to pharmaceutical companies and academic institutions for efficient and effective target discovery and drug development, TH is developing clinical tests, enabling physicians to tailor optimized therapies for patients based on the biomarker profile of each patient's disease specimen. The technology, developed by the company's scientific co-founders, Drs. Emanuel Petricoin and Lance Liotta, was first published in 2001 and in the past 2 years has been used in studies published in more than 50 peer-reviewed journals and presentations. TH's technology was also successfully used in NCI-sponsored clinical trials. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com/.


'/>"/>
SOURCE Theranostics Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
2. Theranostics Health Receives Green Light to Perform Clinical Testing
3. American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission
4. New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
5. Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels
6. MedNet Solutions Certified to Score SF-12v2 Health Survey
7. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
8. First Human Study to Show Sun Chlorella A Supports Heart Health
9. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
10. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):